Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (6): 1566-1573.doi: 10.13481/j.1671-587X.20220623

• Research in clinical medicine • Previous Articles     Next Articles

Effect of transient prematur of luteinizing hormone in gonadotropin releasing hormone antagonist flexible protocols on pregnancy outcomes of patients underwent fresh IVF/ICSI-ET cycles

Hong GAO,Li LIN,Xiaohong YAN,Ping TAO,Youzhu LI()   

  1. Department of Reproductive Medicine,First Affiliated Hospital,Xiamen University,Xiamen 361003,China
  • Received:2022-04-27 Online:2022-11-28 Published:2022-12-07
  • Contact: Youzhu LI E-mail:232398106@qq.com

Abstract:

Objective To compare the pregnant outcomes of the patients with and without transient premature of luteinizing hormone (LH) in gonadotrophin releasing hormone(GnRH) antagonist flexible protocols who underwent fresh in vitro fertilization / intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET) cycles, and to explore whether transient premature had adverse effect on the pregnancy outcomes. Methods The clinical data of 145 IVF/ICSI-ET patients who received flexible antagonist regimen to promote ovulation were analyzed retrospectively. They were divided into non-transient premature of LH group (n=105) and transient premature LH group (n=40)according to whether the patients had the transient premature of LH.The clinical indicators, laboratory indicators and clinical pregnancy outcomes of the patients were compared between two groups. Results There were no significant differences in the average age, infertility years,body mass index(BMI), basic follicular stimulating hormone(FSH), basic LH, basic estradiol(E2), anti-Mullerian hormone(AMH), number of basic antral follicles(AFC), percentages of the patients with poor ovarian reserve and polycystic ovarian syndrome(PCOS) patients between two groups (P>0.05).The gonadotropin(Gn)days, LH level and E2 level on the initial day of antagonists of the patients in transient premature of LH group were higher than those in non-transient premature of LH group (t=-3.251, P= 0.001; t=-10.198,P<0.001; t=3.233,P=0.002), while the days of antagonist use were less than those in non-transient premature of LH group (t=3.090, P=0.003). There were no significant differences in follicular diameter on the initial day of antagonists, E2 and progesterone(P)levels and endometrial thickness on the trigger day, number of available oocytes, numbers(rates) of MⅡ oocytes, numbers(rates) of normal fertilization, numbers(rates) of D3 available embryos, numbers(rates) of D3 high-quality embryos, embryo implantation rates, clinical pregnancy rates and ongoing pregnancy rates of the patients between two groups (P>0.05). The multivariate Logistic regression analysis results showed that the Gn days and E2 level on the initial day of antagonists were the risk factors for the transient premature of LH of the patients underwent fresh IVF/ICSI-ET cycle antagonist flexible protocol[OR (95%CI)=1.516(1.128-2.038),P=0.006;OR(95%CI)=2.424(1.345-4.371),P=0.003]. Conclusion The transient premature of LH of the patients with antagonist flexible protocol during superovulation does not affect the pregnancy outcomes, but it is necessary to control the increased LH level in time and pay attention to the timing of adding antagonists.

Key words: Antagonist regimen, Luteinizing hormone, Pregnancy outcome, In vitro fertilization/intracytoplasmic sperm injection-embryo transfer

CLC Number: 

  • R714.8